AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 13, 2022 for Aayush Agrawal Trustee Aayush Agrawal Trust AJANTA PHARMA LTD. - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are pleased to enclose herewith certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2022 received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company. AJANTA PHARMA LTD. - 532331 - Increase In Volume
In this regard we hereby clarify that as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we have timely disclosed to the Exchanges all the information/events that have a bearing on the operations/performance of the Company and no such material information /event have remained to be disclosed. Since the shares of the Company are freely traded on the Stock Exchange, the Company is unable to comment on the movement in share price of the Company. The Company has always abided by and complied with all the disclosures and regulatory requirements and is meticulously following all the Corporate Governance norms. AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and 'Ajanta's Code of Conduct for Insiders', the Trading Window for dealing in securities of the Company shall remain closed for Designated Persons (as defined in the Code) from close of business hours of 30th September 2022 till 48 hours after the declaration of Unaudited Financial Results of the Company for the second quarter and half year ended 30th September 2022. AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and 'Ajanta's Code of Conduct for Insiders', the Trading Window for dealing in securities of the Company shall remain closed for Designated Persons (as defined in the Code) from close of business hours of 30th September 2022 till 48 hours after the declaration of Unaudited Financial Results of the Company for the second quarter and half year ended 30th September 2022. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 19, 2022 for Aayush Agrawal, Trustee Aayush Agrawal Trust AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 14, 2022 for Ravi Agrawal, Trustee Ravi Agrawal Trust AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 08, 2022 for Ravi P Agrawal, trustee Ravi Agrawal Trust AJANTA PHARMA LTD. - 532331 - US FDA Inspection Of Our Dahej Facility
This is to inform you that our formulation facility at Dahej was inspected by US FDA from 5th September 2022 to 9th September 2022. At the end of the inspection, Form 483 was issued to us with 2 procedural observations. We are in the process of responding to the same within the stipulated time prescribed by US FDA. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 07, 2022 for Ravi Agrawal, Trustee Ravi Agrawal Trust